Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
1,886
Views
0
CrossRef citations to date
0
Altmetric
Genetic Disease

Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab

Chintal H. Shaha Takeda Pharmaceuticals USA, Inc, Lexington, MA, USA;b Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0002-0225-507X
ORCID Icon,
Nicole Princicc Merative, Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0003-3127-4365
ORCID Icon,
Kristin A. Evansc Merative, Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0003-0987-1745
ORCID Icon &
Bob G. Schultza Takeda Pharmaceuticals USA, Inc, Lexington, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7023-8378
ORCID Icon
Pages 871-877 | Received 22 May 2023, Accepted 29 Jun 2023, Published online: 13 Jul 2023

References

  • Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132.e3–150.e3. doi: 10.1016/j.jaip.2020.08.046.
  • Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(Suppl 1):S08–S13. doi: 10.2500/aap.2020.41.200050.
  • Zeerleder S, Levi M. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Ann Med. 2016;48(4):256–267. doi: 10.3109/07853890.2016.1162909.
  • Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108–2121. doi: 10.1001/jama.2018.16773.
  • Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy. 2022;77(3):979–990. doi: 10.1111/all.15011.
  • Busse P, Zaragoza-Urdaz R, Betschel S, et al. Impact of lanadelumab on patient-reported outcomes in hereditary angioedema in the US and Canada: interim findings from the EMPOWER study. J Allergy Clin Immunol. 2022;149(2):AB166. doi: 10.1016/j.jaci.2021.12.549.
  • Wedner HJ, Bernstein J, Betschel S, et al. Effectiveness, safety, and patient-reported outcomes (PROs) in patients with hereditary angioedema (HAE) from the United States and Canada treated with lanadelumab: 24-month data from the EMPOWER study. J Allergy Clin Immunol. 2023;151(2):AB131. doi: 10.1016/j.jaci.2022.12.413.
  • Takeda Pharmaceutical Company. Takhzyro prescribing information. 2023. Available from: https://www.shirecontent.com/PI/PDFs/TAKHZYRO_USA_ENG.pdf.
  • Goodyear MD, Lumry WR, Anderson J, et al. Treatment patterns among patients with HAE-1/2: interim analysis findings from the US and Canada participants in the EMPOWER study. Poster presented at: American Academy of Allergy, Asthma & Immunology Annual Meeting; 2022; Phoenix, AZ.
  • Hoaglin DC, Iglewicz B, Tukey JW. Performance of some resistant rules for outlier labeling. JSTOR. 1986;81(396):991–999. doi: 10.1080/01621459.1986.10478363.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.